Compare Revvity Inc (RVTY) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Tilray Brands Inc — how do they compare? Revvity Inc trades at $117.6 (market cap $12.91B), while Tilray Brands Inc trades at $4.69 (market cap $649.42M). The key difference: Revvity Inc is far larger — about 19.9× Tilray Brands Inc's market cap, and Revvity Inc pays a 0.24% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| RVTY | TLRY | |
|---|---|---|
Market Cap | $12.91B | $649.42M |
Sector | Technology | Health |
52-Week High | $117.75 | $21.00 |
52-Week Low | $82.26 | $3.88 |
Enterprise Value | $15.23B | $816.55M |
Dividend Yield | 0.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.
The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.
TLRY trades at $4.68, up 5.88% today, amid bullish technical signals and news-driven momentum. The company reported record fiscal 2026 revenue of $915 million but posted a net loss of $121 million, with profitability challenges persisting. Recent developments include new product launches and partnerships, while analyst sentiment remains mixed with a majority hold rating.
Outlook hinges on revenue growth and margin improvement, but risks include sustained losses, high debt, and competitive pressures. The stock offers speculative appeal if execution improves, yet volatility and dilution concerns warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
